Drug Safety and Pharmacovigilance
TABLE OF CONTENTS
Volume 85, Issue 3 (March 2009)
Editorial |
News & Views |
Perspectives |
State of the Art |
Research |
Discovery & Development |
Regulation and Use |
Corrigendum
In This Issue
In This Issue
In This Issue
Clin Pharmacol Ther 85: 223; doi:10.1038/clpt.2008.299
See also: Article by Muller & BrennanSee also: Article by Ouellet et al. See also: Article by Zhang et al. See also: Article by SeniorSee also: Article by Seligman & OsborneEditorial
Editorial
Drug Safety and the Role of Clinical Pharmacology in the Safe Use of Therapeutics
PK Honig
Clin Pharmacol Ther 85: 225-228; doi:10.1038/clpt.2008.275
News & Views
Highlights
Highlights
Clin Pharmacol Ther 85: 230-231; doi:10.1038/clpt.2008.298
ASCPT News
ASCPT News
Clin Pharmacol Ther 85: 232-233; doi:10.1038/clpt.2008.300
Books
Starting With Serotonin: How a High-Rolling Father of Drug Discovery Repeatedly Beat the Odds
Reviewed by G Pickering
Clin Pharmacol Ther 85: 234-235; doi:10.1038/clpt.2008.248
Perspectives
Opinion
Adding a Medicine to the WHO Model List of Essential Medicines
SP Kishore and BJ Herbstman
Clin Pharmacol Ther 85: 237-239; doi:10.1038/clpt.2008.258
Model-Based Benefit–Risk Assessment: Can Archimedes Help?
R Krishna
Clin Pharmacol Ther 85: 239-240; doi:10.1038/clpt.2008.240
Conference Proceedings
Measuring Benefit and Balancing Risk: Strategies for the Benefit–Risk Assessment of New Medicines in a Risk-Averse Environment
S Walker, N McAuslane, L Liberti and S Salek
Clin Pharmacol Ther 85: 241-246; doi:10.1038/clpt.2008.277
State of the Art
State of the Art
Safety Assessment and Dose Selection for First-in-Human Clinical Trials With Immunomodulatory Monoclonal Antibodies
PY Muller and FR Brennan
Clin Pharmacol Ther 85: 247-258; advance online publication, January 28, 2009; doi:10.1038/clpt.2008.273
Data-Driven Methods to Discover Molecular Determinants of Serious Adverse Drug Events FREE
AP Chiang and AJ Butte
Clin Pharmacol Ther 85: 259-268; advance online publication, January 28, 2009; doi:10.1038/clpt.2008.274
Research
Reports
Impact of the CYP2D6 Genotype on the Clinical Effects of Metoprolol: A Prospective Longitudinal Study
T Rau, H Wuttke, LM Michels, U Werner, K Bergmann, M Kreft, MF Fromm and T Eschenhagen
Clin Pharmacol Ther 85: 269-272; advance online publication, November 26, 2008; doi:10.1038/clpt.2008.218
Interindividual Variation in the Pharmacokinetics of 
9-Tetrahydrocannabinol as Related to Genetic Polymorphisms in CYP2C9
C Sachse-Seeboth, J Pfeil, D Sehrt, I Meineke, M Tzvetkov, E Bruns, W Poser, SV Vormfelde and J Brockmöller
Clin Pharmacol Ther 85: 273-276; advance online publication, November 12, 2008; doi:10.1038/clpt.2008.213
Articles
The Use of a Clinical Utility Index to Compare Insomnia Compounds: A Quantitative Basis for Benefit–Risk Assessment
D Ouellet, J Werth, N Parekh, D Feltner, B McCarthy and RL Lalonde
Clin Pharmacol Ther 85: 277-282; advance online publication, December 10, 2008; doi:10.1038/clpt.2008.235
Are Migraineurs at Increased Risk of Adverse Drug Responses?: A Meta-Analytic Comparison of Topiramate-Related Adverse Drug Reactions in Epilepsy and Migraine
J Luykx, M Mason, MD Ferrari and J Carpay
Clin Pharmacol Ther 85: 283-288; advance online publication, November 5, 2008; doi:10.1038/clpt.2008.203
High Levels of P-Glycoprotein Activity in Human Lymphocytes in the First 6 Months of Life
C Giraud, X Declèves, JY Perrot, S Manceau, E Pannier, G Firtion, JP Morini, H Chappuy, F Batteux, S Chouzenoux, JM Scherrmann, S Blanche and JM Tréluyer
Clin Pharmacol Ther 85: 289-295; advance online publication, November 26, 2008; doi:10.1038/clpt.2008.221
Pharmacogenetics of Modafinil After Sleep Loss: Catechol-O-Methyltransferase Genotype Modulates Waking Functions But Not Recovery Sleep
S Bodenmann, S Xu, UFO Luhmann, M Arand, W Berger, HH Jung and HP Landolt
Clin Pharmacol Ther 85: 296-304; advance online publication, November 26, 2008; doi:10.1038/clpt.2008.222
Assessment of the Impact of Renal Impairment on Systemic Exposure of New Molecular Entities: Evaluation of Recent New Drug Applications
Y Zhang, L Zhang, S Abraham, S Apparaju, T-C Wu, JM Strong, S Xiao, AJ Atkinson Jr, KE Thummel, JS Leeder, C Lee, GJ Burckart, LJ Lesko and S-M Huang
Clin Pharmacol Ther 85: 305-311; advance online publication, November 19, 2008; doi:10.1038/clpt.2008.208
The CYP3A4*18 Genotype in the Cytochrome P450 3A4 Gene, a Rapid Metabolizer of Sex Steroids, Is Associated With Low Bone Mineral Density
YS Kang, SY Park, CH Yim, HS Kwak, P Gajendrarao, N Krishnamoorthy, S-C Yun, KW Lee and KO Han
Clin Pharmacol Ther 85: 312-318; advance online publication, November 19, 2008; doi:10.1038/clpt.2008.215
Irreversible CYP3A Inhibition Accompanied by Plasma Protein–Binding Displacement: A Comparative Analysis in Subjects With Normal and Impaired Liver Function
R Orlando, S De Martin, P Pegoraro, L Quintieri and P Palatini
Clin Pharmacol Ther 85: 319-326; advance online publication, November 19, 2008; doi:10.1038/clpt.2008.216
Discovery & Development
Translational Medicine
Translational Toxicology and the Work of the Predictive Safety Testing Consortium
WB Mattes and EG Walker
Clin Pharmacol Ther 85: 327-330; advance online publication, January 21, 2009; doi:10.1038/clpt.2008.270
Development
Monitoring for Hepatotoxicity: What Is the Predictive Value of Liver "Function" Tests?
JR Senior
Clin Pharmacol Ther 85: 331-334; advance online publication, January 7, 2009; doi:10.1038/clpt.2008.262
Regulation and Use
Public Policy
Perspectives on Early Communication of Drug Risks to the Public
PJ Seligman and SF Osborne
Clin Pharmacol Ther 85: 335-339; advance online publication, January 21, 2009; doi:10.1038/clpt.2008.272
